DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Luxembourg ONLY.

Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)

NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Report an Adverse Event (AE)

Reporting suspected adverse reactions after authorisation of the vaccine is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Luxembourg.

Centre Régional de Pharmacovigilance de Nancy
Bâtiment de Biologie Moléculaire et de Biopathologie (BBB)
CHRU de Nancy – Hôpitaux de Brabois
Rue du Morvan
54 511 VANDOEUVRE LES NANCY CEDEX
Tél: (+33) 3 83 65 60 85 / 87
e-mail: [email protected]

or

Direction de la Santé
Division de la Pharmacie et des Médicaments
20, rue de Bitbourg
L-1273 Luxembourg-Hamm
Tél.: (+352) 2478 5592
e-mail: [email protected]

Link to the notification form: www.guichet.public.lu/fr/entreprises/sectoriel/sante/medecins/notification-effets-indesirables-medicaments.html

Contact Us

Tel: +352 20 33 17 08
09:00 - 17:00
Monday - Friday